Status:
COMPLETED
Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy
Lead Sponsor:
Indonesia University
Conditions:
Proliferative Vitreoretinopathy
Rhegmatogenous Retinal Detachment
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
PVR remains the major cause of surgical failure in RRD repair.1 Prompt surgical management is the standard therapy in RRD repair. However, in many places, vitreoretinal (VR) surgery facilities is limi...
Detailed Description
Prospective subjects underwent Vital signs, an eye examination, fundus biomicroscopy, fundus photographs, and an Optical Coherent Tomography (OCT) scan of the macula were performed. This initial eye e...
Eligibility Criteria
Inclusion
- ARR with PVR grade A and B
- ARR onset more than 7 days and less than 1 month
- Macula off
- ARR patients with a minimum age of 18 years.
- Willing to follow the research stages and sign the informed consent.
Exclusion
- ARR patients with media opacities that do not allow fundus examination
- History of undergoing intraocular surgery less than 3 months.
- ARR patients with comorbid eye diseases.
- ARR patients with systemic complications that make it impossible to undergo vitrectomy surgery.
- ARR sufferers who are known to have a history of allergies to the NSAID group.
Key Trial Info
Start Date :
April 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT07162818
Start Date
April 28 2021
End Date
December 1 2021
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo Hospital
Jakarta, Jakarta Pusat, Indonesia